A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia

Clinical Neuropharmacology

Volumn 33, Issue 1, 2010, Pages 22-26

  Barasnevicius Quagliato, Elizabeth Maria Aparecida ^a   Carelli, Edmur Franco ^a   Viana, Maura Aparecida ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Botulinum toxin type A; Cervical dystonia; Randomized clinical trial

Indexed keywords

BOTULINUM TOXIN A;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BURN; CERVICAL DYSTONIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INJECTION; LOW DRUG DOSE; MALE; NEUROLOGIC EXAMINATION; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SHORT FORM 36; SOCIAL ASPECT; THERAPY EFFECT; TORONTO WESTERN SPASMODIC TORTICOLLIS RATING SCALE; TORTICOLLIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANALYSIS OF VARIANCE; BOTULINUM TOXIN TYPE A; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TORTICOLLIS; YOUNG ADULT;

EID: 76749135203     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181c46f48     Document Type: Article

References (12)

1. Haerer AF. In DeJong's The Neurological Examination. 5th ed. Philadelphia, USA: Lippincott Williams & Wilkins; 1992; Chapter 31: 402-419.
2. Pitanguy I. Quo vadis doctor. Rev Bras Cir 1993;83(6):257-262.
3. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992;56(1):80-99.
4. Brin MF, Jankovic J, Comella C, et al. Treatment of dystonia using botulinum toxin. In: Kurlan R, ed. Movement Disorders. 1st ed. Philadelphia, USA: Lippincot Williams & Wilkins; 1995;Chapter 6:183-246.
5. Anderson T, Tand C, Marsden D. Botulinum toxin for the treatment of spasmodic torticollis and other movement disorders. In: Lozano AM, Gildenberg PL, Tasker RR, eds. Textbook of Stereotactic and Functional Neurosurgery. 1st ed. NY, USA: Springer Verlag; 1998; Chapter109:1059-1069.
6. Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70;1699-1706.
7. Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72: 459-462.
8. Brefel-Courbon C, Simonetta-Moreau M, More C, et al. A pharmacoeconomic evaluation of botulinum toxin in the treatment of spasmodic torticollis. Clin Neuropharmacol 2000;23(4): 203-207.
9. Wang YC, Zhuang H, Huang BG, et al. Preparation of type a botulinum crystalline toxin for the therapeutic and establishment of an experimental animal model. J Biol Prod 1990;3(3):121-125.
10. Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005;65:1423-1429.
11. Chapman MA, Barron R, Tanis DC, et al. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 2007;29(7):1325-1337.
12. Tang X, Wan X. Comparison of Botox with a Chinese type A botulinum toxin. Chin Med J 2000;113(9):794-798.